Latest Financial Results News

AMP Limited’s FY24 Data Pack outlines a solid underlying profit performance despite headwinds, with key insights into its banking, platform, and wealth management divisions.

AMP reported a robust FY24 with underlying NPAT rising 15.1% to $236 million, driven by disciplined cost management and strong cash flows. The company declared a final dividend of 1.0 cents per share and is set to launch a new digital bank in February 2025, signaling strategic growth in wealth and banking sectors.

AMP Limited’s 2024 results reveal a 43% drop in statutory net profit to $150 million, offset by a 15.1% rise in underlying profit to $236 million, alongside the completion of its Advice business sale and the launch of a new digital bank.

GQG Partners delivered robust full-year 2024 results, marked by a 26.9% increase in funds under management and nearly 47% growth in net revenue, underpinned by strong investment performance and strategic initiatives including Private Capital Solutions and a new Abu Dhabi office.

GQG Partners reported a stellar 2024 with net inflows doubling to US$20.2 billion and funds under management climbing nearly 27%, underpinning strong revenue and earnings growth. The firm also expanded its dividend payout range, signaling confidence in future capital management.

GQG Partners Inc. has announced a quarterly ordinary dividend of USD 0.0378 per CDI, payable on March 27, 2025, with an option for Australian dollar conversion at a specified exchange rate.

GQG Partners Inc. reported strong financial results for 2024, with significant increases in revenue, net income, and funds under management, alongside a raised dividend and strategic moves including the deconsolidation of its PCS Master Fund.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Civmec’s 1H FY25 results reveal robust revenue growth and a strong balance sheet, underpinned by a diversified project pipeline and strategic moves into naval shipbuilding and material handling equipment manufacturing.

Civmec Limited reports solid first-half FY25 results with revenue growth and a stable dividend, while navigating margin pressures and advancing strategic projects.